ImmunoPrecise Antibodies Maintains Buy Rating on Strong Canadian Growth and Strategic Divestment

ImmunoPrecise Antibodies' recent divestment of a Dutch facility for $12 million extends its financial runway by at least four quarters and allows for potential margin expansion. The company's Canadian facility, operational since its inception, is showing promising growth with an 83% increase in quarterly orders and a 93% rise in new client orders. Analyst Swayampakula Ramakanth of H.C. Wainwright maintains a Buy rating and a $5 price target.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has recently extended its financial runway by divesting its Dutch facility to AVS Bio for $12 million. This move not only provides the company with a significant cash infusion but also allows for potential margin expansion. The company's Canadian facility, operational since its inception, has shown promising growth with an 83% increase in quarterly orders and a 93% rise in new client orders.

The divestment is a strategic move that aligns with ImmunoPrecise's goal of focusing on its core competencies in AI-driven biotherapeutic research. The additional funds will support the company's ongoing research and development efforts, particularly in the development of its Universal Dengue Vaccine using its LENSai™ platform [1].

Analyst Swayampakula Ramakanth of H.C. Wainwright maintains a Buy rating for ImmunoPrecise Antibodies and has set a $5 price target. This rating reflects the analyst's confidence in the company's growth prospects and the potential for margin expansion [2].

In addition to the financial benefits, the divestment also helps ImmunoPrecise regain Nasdaq compliance. The company has received formal notification from Nasdaq confirming compliance with the minimum bid price requirements, which is a positive development for the company's listing status [3].

ImmunoPrecise's recent earnings call transcript for Q4 2025 highlighted the company's record revenue of $7 million, with gross margin improving to 64% from 48% YoY. The BioStrand segment grew by 180% YoY, driven by the company's innovative approach to antibody discovery and development [4].

Overall, the divestment of the Dutch facility is a strategic move that positions ImmunoPrecise Antibodies for future growth and success.

References:
[1] https://www.investing.com/equities/tanqueray-exploration-ltd
[2] https://www.investing.com/equities/tanqueray-exploration-ltd
[3] https://www.investing.com/equities/tanqueray-exploration-ltd
[4] https://www.investing.com/equities/tanqueray-exploration-ltd